Member Info for goldust88

Recent share price highs could well be linked to Futuras cannabis product they have been working on- CBD 1OO
-from their RNS 4Tth August--
"James Barder, Chief Executive of Futura Medical commented: "Our R&D team's development work on CBD100 is further evidence of the broad utility and power of the Dermasys system for effective and controlled transdermal delivery of a wide range of active pharmaceutical ingredients (APIs). We are aiming for CBD100 to be highly differentiated from existing, largely un-regulated, low-tech products in the fast growing cannabidiol market on the basis of quality, stability and efficient delivery to the skin for a number of applications and indications expected to range from cosmeceutical through to pharmaceutical dermal and pain relief treatments. We have now started to explore commercialisation options for CBD100 with CBDerma as stability work continues in parallel."
Maybe we could hear quite soon of some sort of deal here or even a seperate stock market listing. Looking at the current value placed on Cannabis stocks .A deal could easily send Futuras share price up 5 fold or more.
If you add the possible value of this to the potential of their MED3000 , topical gel formulation for treatment of erectile dysfunction (ED) well ! The share price could easily exceed a ten bagger.
Like all shares Futura comes with a risk but the rewards could be tremendous even if one of their products is a winner.
If they all come good we could be millionaires Rodney. Futura is only valued £37million
I'm invested heavily as I believe this year will be the year.

They had a share raise last year in November at 3p and that raised over £2.5 million-so take that out of results and you will see how they have really done. It will take some time to raise any sort of reasonable profit.
Selling no4 gives 300% profit-thats pretty good.

Well lets see what the figures are in pounds
"Total Sales Revenue of A$2.1 million (2019: A$1.9 million) up 10%--only equals £1.17 million pounds

Product Revenue of A$1.7 million (2019: A$1.4 million) is up 26%"-only equals £ .0 95 million pounds

Pretty tiny

even double that is small !

Well no news today really and the next court case miles away, so I think we are in for a slow period for quite a while.
Market cap is quite high and probably the company won't be profitable till next year.
Although the product is excellent I'm selling as I think price will drift down for quite a while and its possible no cash will arrive from ioxus case soon, if at all. To keep growing they will need to increase manufacturing ability and that could need more cash!

I would repeat my last comment as although share price has moved up still plenty to go for here -
-Excellent results and dividend to boot with great forward prospects. What more could you want. No effects from Covid on forward work. Re rating will happen over next few weeks as investors digest results see potential.
AND-here is what they say for the future "The size and quality of our growing secured workload at well over £8bn leaves us well-positioned for the future and we are on track to deliver a result which is materially ahead of our previous expectations and slightly ahead of that delivered in 2019."

Maybe news is coming on the Futura Cannabis treatment-an excerpt from their news last year is as follows--

James Barder, Chief Executive of Futura Medical commented: "Our R&D team's development work on CBD100 is further evidence of the broad utility and power of the Dermasys system for effective and controlled transdermal delivery of a wide range of active pharmaceutical ingredients (APIs). We are aiming for CBD100 to be highly differentiated from existing, largely un-regulated, low-tech products in the fast growing cannabidiol market on the basis of quality, stability and efficient delivery to the skin for a number of applications and indications expected to range from cosmeceutical through to pharmaceutical dermal and pain relief treatments. We have now started to explore commercialisation options for CBD100 with CBDerma as stability work continues in parallel."

From July rns-
Meanwhile, the Board will continue to negotiate with potential funding partners for additional investment in the Company and/or its subsidiaries. Whilst terms for any such investment have not been agreed, and there can be no guarantee that such negotiations will be successful, to further reassure shareholders, the Board wishes to make clear that any proposal approved by the Board would (i) be at an implied net asset value per share ("NAV") equal to or not less than £0.06, being a 8.5% premium to the last published NAV, and (ii) existing shareholders of the Company would have the opportunity to participate on the same terms as any new investment.
This to me implies that future fundraises will be about asset value--share price currently is way higher than asset value !

Well share price today just broken out of current 7 month trend-if it goes higher tomorrow then could really move.

Could well be a deal coming as they have hinted at this for quite a time.
Or is it a pump before a fund raise ?
Soon we should know so place your bets. Mines a buy.

Looks to me that a deal will be announced soon with Big pharma !
Price will be a lot higher than today when one is announced.

Raven Russia with a massive holding of wharehouses in Russia - now with share overhang gone this really cheap stock will just keep on paying divs and rising in price--should get back to previous highs this year at about 140p and still pay dividend of 7%
Look at other wharehouse companies and see how prices have risen.
GET IN.

Update today . Asset value 403p with cash of £233 million -. Share price of only 292 p which is a discount of over 26% to the asset value. Increases in value year after year at a great rate-well undervalued-more share price buybacks in the pipeline also to narrow discount. A Simon Thomson favourite.

From July rns-
Meanwhile, the Board will continue to negotiate with potential funding partners for additional investment in the Company and/or its subsidiaries. Whilst terms for any such investment have not been agreed, and there can be no guarantee that such negotiations will be successful, to further reassure shareholders, the Board wishes to make clear that any proposal approved by the Board would (i) be at an implied net asset value per share ("NAV") equal to or not less than £0.06, being a 8.5% premium to the last published NAV, and (ii) existing shareholders of the Company would have the opportunity to participate on the same terms as any new investment.
This to me implies that future fundraises will be about asset value--share price currently is way higher than asset value !

Share price has risen to maybe 100% above asset value here so its time to be careful and take part or all profits.
This is because they have stated that they want to raise more funds and the price to do this would be around asset value=so if this happens shortly could be a big drop in share price.
See previous rns's which state this.

What could be on the cards here is news on their TRUCKSTART supercapacitor, which has been on trials with Truck manufacturers for a couple of years. A deal in the truck field would really set the shares alight.
Also with the number of hybrid and electric cars now taking to the road and the charging stations being set up-they will all use supercapacitors so there is a vast market that there products can launch into and supercapacitors for these uses command much higher values than the ones in use at the moment. CPX has got to be one of the winners in the green revolution. This is the beginning of something big.

There is no chance of this happening ---they have already warned that the price has a lot further to drop.

Share price has moved up nicely touching 84p today. I am expecting this to get some mention in the press sometime soon--but share price should be a lot higher in 6 months time as progress continues,

Part of the report------
Genetic differences were also found in a gene called DPP9, which plays a role in inflammation, and in a gene called OAS, which helps to stop the virus from making copies of itself.
Variations in a gene called IFNAR2 were also identified in the intensive care patients.
IFNAR2 is linked to a potent anti-viral molecule called interferon, which helps to kick-start the immune system as soon as an infection is detected.
It’s thought that producing too little interferon can give the virus an early advantage, allowing it to quickly replicate, leading to more severe disease.
THEREFORE USING INTERFERON AS SNG's STUFF WILL KILL THE VIRUS!
Brilliant

You may have been here longer than I have been out of nappies-but you ---are still wearing them !

New ceo seems to be doing a very good job here.
With profits expected to be about£28 million for the year this is very undervalued at a market cap of £121 million
I am not surprised they have been undergoing a share buy in.
If he goes on improving the situation the share price could really rerate.